lunsumio
roche registration gmbh - mosunetuzumab - limfom, folicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
lunsumio 1 mg
roche pharma ag - germania - mosunetuzumabum - conc. pt. sol. perf. - 1mg - anticorpi monoclonali si conjugati
lunsumio 30 mg
roche pharma ag - germania - mosunetuzumabum - conc. pt. sol. perf. - 30mg - anticorpi monoclonali si conjugati